Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LOXL2 | Q9Y4K0 | 16/20 | 0.61 |
| ▸ | LOX | P28300 | 5/20 | 0.61 |
| ▸ | LOXL3 | P58215 | 1/20 | 0.61 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.47 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.40 |
| ▸ | NOS3 | P29474 | 1/20 | 0.40 |
| ▸ | NOS1 | P29475 | 1/20 | 0.40 |
| ▸ | NOS2 | P35228 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL5013442 | 0.98 | LOXL2 (0.59) | LOXL2LOXLOXL3ROCK1ADRB2 | |
| SCHEMBL1654460 | 0.84 | LOXL2 (0.55) | LOXL2LOXLOXL3ROCK1NOS3 | |
| SCHEMBL2642380 | 0.84 | RECQL (0.55) | LOXL2LOXLOXL3NOS3NOS1 | |
| SCHEMBL15200880 | 0.84 | NOS3 (0.61) | LOXL2LOXLOXL3NOS3NOS1 | |
| SCHEMBL16583871 | 0.84 | LOXL2 (0.52) | LOXL2LOXLOXL3ADRB2 | |
| SCHEMBL9817617 | 0.84 | LOXL2 (0.55) | LOXL2LOXLOXL3ROCK1 | |
| Hydrochloric Acid SCHEMBL17372124 | 0.82 | LOXL2 (0.53) | LOXL2LOXLOXL3ROCK1 | |
| SCHEMBL352525 | 0.80 | LOXL2 (0.61) | LOXL2LOXLOXL3ROCK1ADRB2 | |
| SCHEMBL25203651 | 0.79 | LOXL2 (0.59) | LOXL2LOXLOXL3ROCK1 | |
| SCHEMBL10651314 | 0.79 | LOXL2 (0.46) | LOXL2LOXLOXL3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040157834-A1 | Somatostatin antagonists and agonists that act at the SST subtype 2 receptor | PFIZER INC | 2004-08-12 | — | — | US | claimed |
| US-6720330-B2 | INCREASING SECRETION OF GROWTH HORMONE, GASTRIN, OR GLUCAGON IN A MAMMAL; INHIBITING THE BINDING OF SOMATOSTATIN TO AN SST2 RECEPTOR | PFIZER INC. | 2004-04-13 | — | — | US | claimed |
| US-20020091125-A1 | Somatostatin antagonists and agonists that act at the SST subtype 2 receptor | HAY BRUCE A (US) | 2002-07-11 | — | — | US | claimed |
| EP-2657214-B1 | PROCESS FOR PRODUCTION OF AROMATIC ALCOHOL OR HETEROCYCLIC AROMATIC ALCOHOL | MITSUBISHI GAS CHEMICAL CO (JP) | 2017-02-15 | — | — | EP | disclosed |
| US-8993774-B2 | Process for production of aromatic alcohol or heterocyclic aromatic alcohol | MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) | 2015-03-31 | — | — | US | disclosed |
| US-20130303775-A1 | PROCESS FOR PRODUCTION OF AROMATIC ALCOHOL OR HETEROCYCLIC AROMATIC ALCOHOL | MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) | 2013-11-14 | — | — | US | disclosed |
| EP-2657214-A1 | PROCESS FOR PRODUCTION OF AROMATIC ALCOHOL OR HETEROCYCLIC AROMATIC ALCOHOL | Mitsubishi Gas Chemical Company, Inc. (JP) | 2013-10-30 | — | — | EP | disclosed |
| US-8247430-B2 | Substituted aryl-amine derivatives and methods of use | AMGEN INC. (US) | 2012-08-21 | — | — | US | disclosed |
| US-20090143355-A1 | Substituted aryl-amine derivatives and methods of use | AMGEN INC. (US) | 2009-06-04 | — | — | US | disclosed |
| US-20040157834-A1 | Somatostatin antagonists and agonists that act at the SST subtype 2 receptor | PFIZER INC | 2004-08-12 | — | — | US | disclosed |
| US-6720330-B2 | INCREASING SECRETION OF GROWTH HORMONE, GASTRIN, OR GLUCAGON IN A MAMMAL; INHIBITING THE BINDING OF SOMATOSTATIN TO AN SST2 RECEPTOR | PFIZER INC. | 2004-04-13 | — | — | US | disclosed |
| US-20020091125-A1 | Somatostatin antagonists and agonists that act at the SST subtype 2 receptor | HAY BRUCE A (US) | 2002-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130303775-A1 | PROCESS FOR PRODUCTION OF AROMATIC ALCOHOL OR HETEROCYCLIC AROMATIC ALCOHOL | ADH1C, ADH1A, ADH5 | LOXL2 3456/4885LOX 1905/4885LOXL3 2432/4885 |
| US-20040157834-A1 | Somatostatin antagonists and agonists that act at the SST subtype 2 receptor | SSTR2, GHSR, SSTR1 | LOXL2 3186/4885LOX 3542/4885LOXL3 3410/4885 |
| US-20090143355-A1 | Substituted aryl-amine derivatives and methods of use | FLT1, FLT4, NAT1 | LOXL2 1563/4885LOX 729/4885LOXL3 1561/4885 |
| US-20020091125-A1 | Somatostatin antagonists and agonists that act at the SST subtype 2 receptor | SSTR2, GHSR, SSTR1 | LOXL2 3246/4885LOX 3606/4885LOXL3 3425/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.